Trials Sponsors Conditions Drugs Pricing

Conditions

Condyloma Acuminata Wart; External Genital Organs

Outcome Measures

Primary Outcomes (1)

The number of patients with Adverse Events and their severity
up to 16 weeks

Secondary Outcomes (5)

Number of patients with complete and partial clearance of external genital warts
16 weeks
Number of warts that were completely or partially cleared
16 weeks
Time to complete clearance
16 weeks
Recurrence rate in treatment area
3 months follow up
Time to recurrence
3 months follow up

Study Arms (1)

Topical AS101

EXPERIMENTAL

15% AS101 ointment applied twice a day for treatment of external genital warts.

Drug: Topical AS101

Interventions

Topical AS101Drug

AS101 15% ointment will be applied topically twice daily on external genital warts for up to 16 weeks.

Topical AS101

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexfemale

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Women 18 years of age and in good health;
Must sign an ethics committee approved informed consent form and be able to adhere to study visits and protocol requirements;

Sponsors & Collaborators

BioMAS Ltd
Industrylead

Study Sites (1)

Gynecology department, Haemek MC

Afula, Israel

MeSH Terms

Conditions

Warts

Interventions

ammonium trichloro(dioxoethylene-O,O'-)tellurate

Condition Hierarchy (Ancestors)

Papillomavirus InfectionsDNA Virus InfectionsVirus DiseasesInfectionsSkin Diseases, ViralTumor Virus InfectionsSkin Diseases, InfectiousSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

Shabtai Romano, MD
Ha'Emek Medical Center, Afula, Israel
PRINCIPAL INVESTIGATOR

Enrollment

12 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 1 2
Allocation: NA
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

March 11, 2012

First Posted

March 15, 2012

Study Start

March 2012

Date type not reported

This date has not been verified as actual or estimated.

Safety and Efficacy Study to Test Topical AS101 for External Genital Warts

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (5)

Study Arms (1)

Topical AS101

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (5)

Study Arms (1)

Topical AS101

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations